and present with consequent endocrinopathy, or they may be endocrinologically inactive and present with hypopituitarism and/or visual loss as a result of suprasellar extension of the mass. 3 Although pituitary adenomas are most often found to be benign on histological examination, they often invade adjacent structures, reducing the chances for surgical cure. 41 Transformation of an adenoma to metastatic carcinoma rarely occurs but is well documented. 32 Previous molecular genetic studies of pituitary adenomas have revealed relatively few genetic aberrations. A point mutation activates the gsp oncogene 22 in approximately one third of growth hormone-secreting adenomas, 35 but seldom in other subtypes. 5, 37 Studies of such known oncogenes as ras, myc, fos, bcl1, H-stf1/fgf4, and sea 5, 12, 18 and of tumor suppressor genes including p53 12 and Rb 8, 43 have also been negative. Allelotype analyses 5, 12 reveal that chromosome 11q is the most common site of loss, and loss in other regions occurs much less often. Aberrations of chromosomes 1, 4, 7, and 19 are the ones most frequently found in tumor karyotypes. 
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Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization Allelotyping is hampered by its inability to examine the entire tumor genome for aberrations. Moreover, because allelotyping is designed primarily to detect loss of heterozygosity, it may be insensitive to other types of genetic aberrations, such as gain of genetic material. Although karyotype analysis of adenomas partially addresses such problems, it relies on the establishment of primary cultures, thus introducing selection and its potential artifacts. 15 We therefore conducted a study of pituitary adenomas by using comparative genomic hybridization (CGH), a molecular cytogenetic technique that detects genetic aberrations across the entire tumor genome. 17 For this technique, genomic DNA from tumor and normal tissue are separately labeled with green and red fluorochromes. The genomic probes are then simultaneously hybridized to normal metaphase chromosomes. This "paints" the chromosomes with red and green signals from the normal and tumor DNA. If CGH is conducted using green-labeled tumor and red-labeled normal genomic DNA, the metaphase template will appear green if there has been relative gain, red if there has been relative loss, and yellow if there has been no change in the genetic content of the tumor. A quantitative image processing system is used to collect the data and map copy number aberrations (CNAs) to specific chromosomal subregions.
Materials and Methods

Patients and Adenoma Specimens
Pituitary adenomas (40 primary, 13 recurrent) resected from 26 male and 26 female patients were selected for analysis from a total of 153 specimens stored in the Brain Tumor Research Center (BTRC) Tissue Bank at the University of California San Francisco (UCSF). The specimens were obtained from consecutive patients in whom the tumor size was sufficient for submission of a sample to the bank; the operations had been performed at UCSF by one neurosurgeon (C.B.W.) between July 1992 and July 1995. To obtain samples from all clinical subtypes, the study group of 53 adenomas was selected from all banked endocrinologically inactive adenoma specimens larger than 0.15 g, all endocrinologically active adenoma specimens larger than 0.1 g, and all recurrent adenoma specimens larger than 0.01 g.
After surgical removal, the tumor specimens were flash-frozen in liquid nitrogen and stored at Ϫ80˚C in the BTRC Tissue Bank, where a sample number was assigned to maintain patient confidentiality. The collection and storage of samples were in accordance with the guidelines of the UCSF Committee on Human Research. The samples are listed in numerical order and the numbering includes the prefix "SF" to designate that they were obtained at our institution (Table 1) .
Adenomas were characterized based on intraoperative findings. Tumor size was an estimated aggregate diameter of the viable mass, except for cases in which a cystic component was present. The adenoma was considered recurrent rather than residual if the primary adenoma had been resected more than 9 months earlier (disease-free interval range 10 months-29 years, mean 13.75 years). Two patients presented with adenomas that ultimately transformed to carcinoma; those adenomas comprised sample SF2029 from one patient and samples SF2353 and SF2602 obtained in separate operations performed in the other patient. No patients in this study were known to have a familial syndrome, such as multiple endocrine neoplasia type I.
Histopathological Examination
Hematoxylin and eosin-stained cryosections of each banked sample considered for analysis were examined by a neuropathologist (A.W.B.). Samples were excluded from the study if the diagnosis could not be confirmed or if the banked sample contained less than 50% adenoma tissue. The majority of specimens contained more than 75% adenoma tissue.
Extraction and Labeling of DNA
Total genomic DNA was extracted from each tumor sample and from peripheral leukocytes of normal male and female volunteers by using a standard protocol of alkaline lysis, proteinase K treatment, and phenol extraction as described elsewhere. 31 The DNA samples were labeled directly by using nick translation in the presence of either fluorescein isothiocyanate-12-deoxyuridinetriphosphate (green labeling) or Texas red-5-deoxyuridinetriphosphate (red labeling). The enzyme concentration and digestion time were adjusted to yield probe fragment sizes from 200 to 2000 bp as assessed on agarose gel electrophoresis.
Comparative Genomic Hybridization
Comparative genomic hybridization was performed as described. 24 Slides containing normal metaphase spreads were prepared from phytohemagglutinin-stimulated peripheral blood lymphocytes obtained using standard protocols from a healthy male donor. Slides were denatured in 70% formamide/2 ϫ SSC (1 ϫ SSC = 0.15 M sodium chloride, 0.015 M sodium citrate, pH 7) at 75˚C for 4 to 7 minutes (optimized for each slide set), dehydrated in a graded alcohol series, air dried, and placed in a slide warmer at 37˚C. Green-labeled adenoma DNA (200 ng), red-labeled normal DNA (200 ng), and 20 g of Cot-1 DNA were combined, ethanolprecipitated, and resuspended in 10 l of 50% formamide, 10% dextran sulfate, and 2 ϫ SSC. The probe mixture was denatured at 80˚C for 5 minutes and hybridized to the denatured normal metaphase chromosomes at 37˚C for 48 hours. Slides were washed at 45˚C for 10 minutes in three changes of 50% formamide/2 ϫ SSC, two changes of 2 ϫ SSC, and once in 0.1 ϫ SSC. They were then washed at room temperature for 10 minutes each in 4 ϫ SSC, 4 ϫ SSC/0.1% Triton, 4 ϫ SSC, and phosphate buffer with 0.1% NP-40, pH 8. Slides were counterstained with 0.2 M 4,6-diamino-2-phenylindole in an antifade solution.
The CGH image analysis was performed as described. 27 A fluorescence microscope with a charge-coupled device camera was used in conjunction with a quantitative image processing system on a computer workstation to acquire the red, green, and blue images from several metaphase spreads. The chromosomes were identified by their 4,6-diamino-2-phenylindole banding pattern, and the relative green/red ratios were calculated along each chromosome by using image analysis software. 27 For each tumor, at least eight samples of each autosome and four samples of each sex chromosome were used to calculate confidence intervals. Similar analyses were performed on hybridizations of green-and red-labeled normal genomic DNA samples. Tumors were then scored for CNAs along each chromosome, with genetic gain defined by a confidence interval entirely above 1.2 and loss defined by intervals entirely less than 0.8. These cutoff values were based on analysis of a series of normal/normal hybridizations. 24 The fluorochromes were reversed (tumor DNA labeled red, normal DNA labeled green) for all cases in which definitive results were not obtained, and CNAs were scored only if the aberration was present in both the "forward" and the "reverse" experiments.
Immunoperoxidase Staining With Cyclin D1
Formalin-fixed paraffin-embedded tissues from 16 of the tumors studied using CGH were stained with a mouse monoclonal antibody for cyclin D1. This group of adenomas, chosen to represent the different CNA types observed, included the four with evidence of 11q13 rearrangement, four with other chromosome 11 CNAs, three with aberrations on chromosomes other than 11, and five with no CNAs. In brief, 5-m sections were mounted, baked at 60˚C for 30 minutes, deparaffinized in xylene, rehydrated in a graded ethanol series, quenched of endogenous peroxidase with 3% hydrogen peroxide, and microwaved in 10 mM citrate buffer for 10 minutes. After treatment with blocking serum, the slides were incubated with * Cav = cavernous; ext = extension; pri = primary; rec = recurrent; RT = radiation therapy; sphe = sphenoid; + = present; -= absent. † The gross tumor description is based on intraoperative findings and has been left blank when the information was unavailable. ‡ Clinical subtypes are indicated as follows: A = acromegaly (seven patients); C = Cushing's disease (seven adenomas, six patients); N = endocrinologically inactive adenoma (32 patients); P = prolactinoma (six patients); and T = thyrotrophinoma (one patient).
§ The CGH categories are as follows: A = 11q13 rearrangement; B = chromosome 11 abnormality other than A; C = CNAs involving chromosomes other than 11; and D = no abnormalities detected by CGH.
For cyclin D1 staining results, ¥ = positive immunoperoxidase staining more than 5% of nuclei; o = no nuclear positivity; and blank = not tested. Note that none of the four tumors with evidence of 11q13 rearrangement showed evidence of cyclin D1 expression. ** Samples SF2353 and SF2602 were derived from two separate operations in the same patient. a 1:20 dilution of the primary antibody at 37˚C for 1 hour and then a biotinylated horse anti-mouse antibody. The slides were washed in phosphate-buffered saline, incubated with the avidin-biotin peroxidase complex reagent, and developed with diaminobenzidine tetrahydrochloride. After rinsing in running tap water, the slides were counterstained, dehydrated, and mounted on coverslips. Positive control tissues included formalin-fixed paraffin-embedded sections of breast carcinoma (B326) that is known to have amplification of the 11q13 region by fluorescence in situ hybridization (F Waldman, personal communication, 1996) and cell line A431. The slides were interpreted by a neuropathologist (A.W.B.) who was blinded to the CGH results. Slides were scored positive if they contained more than 5% positive nuclei per 400 hpf.
Statistical Analysis
The clinical data and tumor characteristics (Table 1) were tested for associations with the CGH results by using a commercially available statistical software package. These latter variables included presence and number of aberrations as well as specific aberrations (for example, loss on chromosome 11, gain on chromosome 7) and aberration types (for example, whole chromosome gain, chromosome arm loss) that were detected in five or more adenomas. The analysis included the aberrations present in sample SF2353 but not those in sample SF2602 to avoid representing the same patient twice.
To identify the clinical parameters most closely associated with abnormal tumor characteristics, backward stepwise multivariate models were used, with parameters remaining in the model if the probability value was less than or equal to 0.05. When the tumor characteristic was a number (for example, number of aberrations), standard regression analysis was used, and when the characteristic was categorical (presence or absence of abnormalities), logistic regression was used. These preliminary analyses were performed using the standard approximations. Because the sample sizes were small in this study, the final models were reconfirmed using exact testing procedures. For all tumor characteristics, the multivariate model selected no more than one clinical predictor. Therefore it was possible to use the exact Wilcoxon rank sum test 40 and Fisher's exact test 9 for numerical and categorical outcomes, respectively.
Sources of Supplies and Equipment
The BioNick labeling system and the Cot-1 DNA were purchased from BRL, Gaithersburg, MD. The green-and red-labeling kits were acquired from DuPont, Wilmington, DE. The fluorescence microscope (Axioplan model) was obtained from Carl Zeiss, Thornwood, NY, and the computer workstation (Solaris model) was from Sun Microsystems, Mountain View, CA. The antibody for cyclin D1 (NCL-cyclin-D1) was purchased from Novocastra Laboratories, Newcastle-upon-Tyne, UK. The avidin-biotin-peroxidase reagent (Vectastain Elite) was acquired from Vector Laboratories, Burlingame, CA, and the diaminobenzidine tetrahydrochloride from Sigma Chemical Co., St. Louis, MO. The cell line A431 was obtained from American Type Culture Collection, Bethesda, MD. The statistical software package was purchased from Stat Corp., College Station, TX.
Results
Comparative Genomic Hybridization
Sample CGH preparations and their corresponding green/red profiles are shown in Figs. 1 and 2 , respectively. Hybridization of normal male (green-labeled) and female (red-labeled) genomic DNA to normal male metaphase chromosomes (Fig. 1a) produced chromosomes that appeared yellow (equal amounts of red and green) except for the X chromosome, which appeared red because there was one less copy in the green-labeled male genome relative to the red-labeled female genome. The corresponding ratio profiles for this control experiment (Fig. 2a) showed ratios of 1.0 for the autosomes and 0.5 for the X chromosome, as expected. Hybridization of a primary, endocrinologically inactive adenoma (SF2001) produced a pair of chromosomes that were red except for a small yellow band on the proximal long arm (Fig. 1b) . This chromosome 11 aberration was the sole genetic abnormality in this tumor (Fig. 2b) . Hybridization of a primary prolactinoma (SF2378) produced several green and red chromosomes (Fig. 1c) , and the amount of change from a ratio mean of 1.0 differed among those chromosomes containing aberrations (Fig. 2c) . For example, chromosome 1q has a ratio mean of 1.5, whereas chromosome 3 has a ratio mean of 1.2.
FIG. 1. a:
Three-color fluorescence microscopic image of a control CGH experiment. Normal male metaphase chromosomes were hybridized with green-labeled normal male and red-labeled normal female total genomic DNA. Most chromosomes appear yellow due to equal hybridization of the labeled male and female samples. The X chromosome appears red because the green-labeled male genome contains one less copy of this chromosome than the red-labeled female genome. b: A CGH image of sample SF2001, a primary endocrinologically inactive pituitary adenoma resected in a 67-year-old man. Chromosome 11 appears red except for a yellow band on the proximal long arm, implying that the tumor genome has lost all of at least one copy of chromosome 11 except for the 11q13 region. This was the sole CNA in this tumor. c: A CGH image of sample SF2378, a primary prolactinoma resected in a 63-year-old man. Multiple chromosomes are gained (green) and lost (red) in this tumor. (11q12-11q13) . This is the sole CNA for this adenoma; the remaining chromosomes demonstrate normal ratios of 1.0. (The low ratio seen near the centromere of chromosome 9 is a repetitive sequence artifact, which is often found in control hybridization.) c: Chart showing CGH ratio profiles for the hybridization of sample SF2378, shown in Fig. 1c . The tumor has multiple abnormalities mostly involving entire chromosomes. Note that the amount of deviation of the ratio from 1.0 varies among chromosomes that were gained and those that were lost.
Copy number aberrations were found in 18 (45%) of 40 patients with primary and seven (58%) of 12 patients with recurrent adenomas or in 25 (48%) of the 52 patients overall (Table 2) . Of 26 adenomas, 18 (69%) contained CNAs on multiple chromosomes. In order of decreasing frequency, the chromosomes affected (Fig. 3) were: 11 (10 adenomas each); 7 and X (nine adenomas each); 1 and 8 (eight adenomas each); 13 (seven adenomas each); 5 and 14 (six adenomas each); 2, 6, 9, 10, and 12 (five adenomas each); 3 (four adenomas each); 18 and 21 (three adenomas each); 4 and 16 (two adenomas each); and 15, 19, 22, and Y (one adenoma each). Most CNAs involved an entire chromosome or chromosome arm, and the most common type of CNA was gain of an entire chromosome (45:100 CNAs detected, 45%). No amplified genomic regions were detected.
We found CNAs affecting chromosome subregions in seven adenomas. The most frequent subregion aberration, which was present in four (8%) of the 53 adenomas, was loss of most or all of chromosome 11p together with loss of all but the most proximal portion of 11q (Fig. 1b) . This was the sole abnormality in three of the four adenomas. Green/red profiles along chromosome 11 for the four tumors with this aberration (Fig. 4) showed that the smallest common region of preservation was the 11q13 region. These results indicate that an unbalanced chromosomal rearrangement involving 11q13 had occurred in these four adenomas.
Two patients in this study had neoplasms that ultimately developed into pituitary carcinomas. The specimen obtained in one of them (SF2029) demonstrated no abnormalities on CGH. Samples obtained in the other patient showed many aberrations (sample SF2353), some of which apparently disappeared or changed to interstitial abnormalities (sample SF2602) after treatment with radiosurgery ( Table 2) .
Statistical Analysis of CGH Results and Clinical Parameters
Endocrinologically active adenomas were associated with the presence of CNAs (p = 0.009), a higher number of CNAs (p = 0.003), gain on chromosome 7 (p = 0.04), loss of whole chromosomes (p = 0.005), and gain of chromosome arms (p Ͻ 0.001). No other clinical factors or adenoma characteristics were significantly associated with the CGH results.
Immunohistochemical Analysis of Cyclin D1 Expression
Expression of cyclin D1 was evaluated in a subset of the adenomas by immunoperoxidase staining of formalinfixed paraffin-embedded tissue (Table 1 ). In six (38%) of the 16 adenomas tested, the nucleus stained positive for the antibody. None of the four adenomas with CNAs involving the 11q13 region showed evidence of cyclin D1 expression.
Discussion
The CGH method allowed us to detect a greater frequency of genetic aberrations in pituitary adenomas than has been found using karyotype 28 and allelotype analyses. 5, 12 This finding was not unexpected because CGH is a reliable method to detect aberrations across the entire genome without the need for primary cultures, and allelotype analysis may be insensitive to copy-number gains, the most frequent type of abnormality observed in this study. Our ability to examine these adenomas at a genome-wide level by using CGH provided new evidence of chromosome 11 rearrangement and the frequent occurrence of aberrations involving entire chromosomes.
Chromosome 11: the Most Frequent Location of CNAs
Chromosome 11 was frequently a site for genetic aberrations, consistent with previously reported allelotype analyses. 5, 12, 35 Our data include a broader spectrum of abnormalities involving this chromosome than has been shown before, and four adenomas demonstrated a loss of all chromosome 11 material except for a preserved common segment containing 11q13. These results emphasize the importance of 11q13 in sporadic pituitary adenoma and indicate that rearrangement of this region may serve as a mechanism for oncogene activation or tumor suppressor gene inactivation in a subset of adenomas. Finer mapping studies with these four adenomas will clarify the relationship between the 11q13 markers lost in the allelo- The gene for the cell cycle regulatory protein cyclin D1 also maps to the 11q13 region, 42 and its overexpression through amplification has been observed in many human carcinomas. 1, 4, 7 Rearrangement at 11q13 occurs in both mantle cell lymphoma 38 and parathyroid adenoma, 2 resulting in overexpression of cyclin D1 in these tumors.
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When we examined the expression of cyclin D1 in a subset of the adenomas that had been studied using CGH, some expressed cyclin D1, but none of the four adenomas with evidence of 11q13 rearrangement tested positive, making this gene an unlikely target for the rearrangement that we observed in pituitary adenomas.
Frequent Detection of Aneusomy
Aneusomy, the loss or gain of whole chromosomes, was observed frequently in this study. The CNAs detected were nonrandom in distribution, and in most instances a particular chromosome was either gained or lost in several adenoma samples (Fig. 3) . This indicates that such genetic events are selected for their ability to confer a growth advantage to the tumor cells in which they occur. However, the fact that many CNAs involved entire chromosomes rather than chromosome subregions raises the possibility that these aberrations do not represent the primary mechanism of oncogene activation or tumor suppressor gene inactivation, but instead are secondary to mutations in genes that regulate chromosomal segregation during cell division. 25 Such genes have been identified in yeast, 11 and when their human counterparts are identified it may be possible to determine whether these aneusomies represent primary or secondary events. Loss or gain of a single copy of genetic material in a homogeneous diploid tumor would be expected to change the green/red ratio by 0.5. However, in this study many of the adenomas with multiple CNAs had ratios that deviated less than 1.0 Ϯ 0.5 and differed between those chromosomes containing aberrations (Fig. 2c) . One explanation for this finding would be polyploidy or multiple aneusomies resulting in the gain or loss of one of three or four instead of one of two copies of genetic material, for example. Another possible explanation for this finding is that such adenomas are composed of a heterogeneous population of cells. Although X-chromosome inactivation studies have shown that pituitary adenomas are monoclonal, 13 that would not exclude the possibility that subclones arise later in the development of the tumor. In that case, those aberrations with a greater degree of green/red deviation would represent earlier genetic changes in the development of the tumor's dominant clone. Fluorescence in situ hybridization experiments using single-copy probes on adenoma touch preparations might clarify the basis of this finding.
Association of CGH-Defined Genotype With Tumor Phenotype
Endocrinologically active adenomas were more likely to contain CNAs and had a greater number of these aberrations than endocrinologically inactive tumors. Because the majority of aberrations detected involved entire chromosomes and chromosome arms, it is not surprising that there were also significant associations with these types of CNAs. Similar trends have been seen with karyotype analysis 28 and image analysis of DNA content. 21 One interpretation of these findings is that secretory and nonsecretory adenomas might be initiated and progress by different mechanisms. Another interpretation is that genomic instability manifested as secondary aneusomies occurs more readily in secretory adenomas because they have a higher proliferative index than nonsecretory types. 36 Many clinical features and tumor characteristics were not significantly associated with the CGH results. Our ability to detect associations may have been limited by our sample size and the resolution of CGH. Although chromosome 11 was the most common site of aberration and may contain an important gene in the 11q13 region, adenomas containing such CNAs did not share features at a statistically significant level. One explanation for this finding is that 11q13 contains an important initiating gene that is affected in all adenomas, and the genetic event that disrupts this gene is detectable by CGH in only a subset of adenomas.
We also noted that the CGH results did not appear to be associated with the adenoma's status as primary or recurrent. Primary adenomas often contained multiple aberrations, and recurrent or aggressive adenomas did not contain a substantially higher number of CNAs. These results seem to differ from accepted models of tumor progression 39 and the findings of one allelotype analysis of pituitary adenomas. 5 It is possible that tumor recurrence may be influenced to a greater degree by other factors, such as surgical technique, that were not directly measurable in this analysis. On the other hand, because CGH gives a more complete view of the tumor genome, we know that the majority of the CNAs were, in fact, aneusomies that may be secondary rather than primary abnormalities. By contrast, CGH analyses of other tumor types that have a more aggressive, malignant phenotype 16, 19, 24 detect subregion CNAs and amplifications at a much higher rate than seen in this study. Our findings indicate that genomic instability manifested as aneusomy may be an early event in tumor development. Additional genetic events, such as the amplification of regions containing oncogenes, may be required for progression to a more aggressive phenotype.
